Abstract
Diabetes mellitus (DM) is a pro-thrombotic state with enhanced thrombin generation and platelet reactivity. For most patients undergoing percutaneous coronary intervention (PCI), bivalirudin demonstrates efficacy comparable with that of heparin and glycoprotein IIb/IIIa inhibitors (GPIs). Yet, because of their pro-thrombotic condition, we hypothesized that patients with DM may benefit from more aggressive dual antithrombin and antiplatelet therapy. The aim of this paper was to provide a systematic review comparing outcomes of PCI with bivalirudin versus heparin plus GPI in patients with DM using meta-analytical techniques. Eligible studies needed to have reported a subgroup analysis of outcomes among diabetic patients. Six trials comprising 5924 diabetic patients were eligible. At 30 days, bivalirudin was associated with a reduction in net adverse cardiac events [relative risk (RR) 0.81, 95 % confidence interval (CI) 0.70-0.93, p = 0.002] and major bleeds (RR 0.68, 95 % CI 0.49-0.95; p = 0.02), with no difference in composite ischemia (RR 0.92, 95 % CI 0.74-1.14; p = 0.43) or mortality (RR 0.71, 95 % CI 0.45-1.13; p = 0.15). At 1 year, bivalirudin was associated with a significant reduction in all-cause mortality (RR 0.73, 95 %...Continue Reading
References
Jan 1, 1990·Annual Review of Cell Biology·D D Wagner
Dec 1, 1988·Diabetes·G M Reaven
Nov 1, 1987·The American Journal of Cardiology·G F LempJ M Sullivan
Jun 10, 1993·The New England Journal of Medicine·D M Nathan
Jan 15, 2000·Lancet·E J TopolR M Califf
Aug 11, 2000·JAMA : the Journal of the American Medical Association·E M AntmanE Braunwald
Jul 27, 2001·Diabetes Care·A I VinikG L Pittenger
Dec 6, 2001·Circulation·M RoffiE J Topol
Jan 15, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·Jukka WesterbackaRiitta Lassila
Sep 13, 2002·Journal of the American College of Cardiology·Tauqir Y GorayaVéronique L Roger
Feb 18, 2003·JAMA : the Journal of the American Medical Association·A Michael LincoffUNKNOWN REPLACE-2 Investigators
Apr 20, 2004·Journal of the American College of Cardiology·Roxana MehranMartin B Leon
Mar 24, 2005·JAMA : the Journal of the American Medical Association·James D Flaherty, Charles J Davidson
Nov 25, 2006·The New England Journal of Medicine·Gregg W StoneUNKNOWN ACUITY Investigators
Mar 31, 2007·Journal of the American College of Cardiology·Steven V ManoukianGregg W Stone
Feb 19, 2008·Journal of the American College of Cardiology·Gjin NdrepepaAdnan Kastrati
Apr 26, 2008·Journal of the American College of Cardiology·Frederick FeitGregg W Stone
May 24, 2008·The New England Journal of Medicine·Gregg W StoneUNKNOWN HORIZONS-AMI Trial Investigators
Aug 16, 2008·The New England Journal of Medicine·Adnan KastratiUNKNOWN ISAR-REACT 3 Trial Investigators
Nov 22, 2008·Journal of the American College of Cardiology·Duane S PintoUNKNOWN ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Investigators
Oct 21, 2009·The American Journal of Cardiology·Davide TavanoCarlo Briguori
Jun 15, 2011·Circulation·Roxana MehranHarvey White
Jul 23, 2011·JACC. Cardiovascular Interventions·Bernhard WitzenbichlerGregg W Stone
Nov 15, 2011·The New England Journal of Medicine·Adnan KastratiUNKNOWN ISAR-REACT 4 Trial Investigators
Oct 11, 2012·Circulation. Cardiovascular Interventions·Gjin NdrepepaGregg W Stone
Nov 1, 2013·The New England Journal of Medicine·Philippe Gabriel StegUNKNOWN EUROMAX Investigators
Jul 9, 2014·Lancet·Adeel ShahzadUNKNOWN HEAT-PPCI trial investigators
Citations
Jun 20, 2015·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Fabio Angeli, Gianpaolo Reboldi
May 18, 2016·The American Journal of Cardiology·Gennaro GiustinoGregg W Stone
Jun 29, 2016·Revista Española De Cardiología·Giuseppe Gargiulo, Marco Valgimigli
Sep 1, 2019·Current Pharmaceutical Design·Alessandra VecchiéAldo Bonaventura
Jan 18, 2017·PloS One·Haiyan XuXiongwei Xie
Jul 21, 2017·Medicine·Juan Zhang, Xinchun Yang